Evotec Se · XETR:EVT
Evotec — Investor Presentation (March 2026)
34 slides from Evotec's investor presentation, March 2026
Slide 1: General company presentation
General company presentation Scientific Operational Excellence Excellence Evotec SE, Company presentation, March 2026
Slide 2: Disclaimer
Disclaimer This presentation (including any information which has been or may be supplied in writing or orally in connection herewith or in connection with any further inquiries) is being delivered on behalf of Evotec SE (the “Company”, “we,” “our” or “us”). This presentation is made pursuant to Sec
Slide 3: Pioneering Drug Discovery / Financials
1 Pioneering Drug Discovery 2 Financials PAGE 3
Slide 4: Unleashing innovation in drug discovery to develop life-changing medicines
Pioneering Drug Discovery Our purpose Unleashing innovation in drug discovery to develop life-changing medicines PAGE 4
Slide 5: Four levers of mid-term value creation
Four levers of mid-term value creation Above market growth rates at better-quality earnings Commitment to Operational Excellence Just – Evotec Biologics – better monetization of technology & assets Upside through returns on asset pipeline PAGE 5 1 Cumulative, non risk adjusted values
Slide 6: Lever 1: Above market growth rates at better-quality earnings
Lever 1: Above market growth rates at better-quality earnings Above market growth rates at better-quality earnings Technological leadership and innovation; steering portfolio towards high value segments Commitment to Operational Excellence Just – Evotec Biologics – better monetization of technology
Slide 7: Operating in highly attractive markets
Operating in highly attractive markets Outsourcing and paradigm shift as drivers for superior growth Global R&D spend Outsourcing share $ 260 bn • Global R&D spend with 3% growth 2023-2030 5-7% 40% Clinical 15% • Outsourcing trend continuing - drug discovery catching up CAGR (addressable CRO market
Slide 8: Innovative D&PD platforms drive high value partnerships
Innovative D&PD platforms drive high value partnerships Seamless AI enhanced DD platforms support expansion of co-owned asset pipeline Patient stratification In silico Target ID/ validation design Data Target ID / Hit Lead Pre-Clinical Clinical Sourcing Validation Identification Optimisation Develop
Slide 9: Versatile commercial model tailor-made to customers' needs
Versatile commercial model tailor-made to customers’ needs Targeted value proposition Our offerings Our value proposition Our commercial position 3 • Access to cutting edge technology, next-gen biology & AI Pioneering drug • Enhance drug discovery & development program Strategic partnerships & disco
Slide 10: Lever 2: Commitment to Operational Excellence
Lever 2: Commitment to Operational Excellence Above market growth rates at better-quality earnings Technological leadership and innovation; steering portfolio towards high value segments Commitment to Operational Excellence Accelerating cost-out plans & further productivity improvement Just – Evotec
Slide 11: Cost-out initiatives ahead of initial plan
Cost-out initiatives ahead of initial plan Cost reduction measures 2025 Impact ~ 600 FTE reduction in D&PD Measure Progress (Mar 24 – Jun 25); +200 FTE vs. Priority Reset Target • Remaining Priority Reset initiatives implemented • Disciplined spending & restricted hiring activities FY 2025 total cos
Slide 12: Lever 3: JEB – better monetization of technology & assets
Lever 3: JEB – better monetization of technology & assets Above market growth rates at better-quality earnings Technological leadership and innovation; steering portfolio towards high value segments Commitment to Operational Excellence Accelerating cost-out plans & further productivity improvement J
Slide 13: Just Evotec Biologics – better monetisation of technology & assets
Just Evotec Biologics – better monetisation of technology & assets Improving operational efficiency by focusing on technology leadership and core competencies Just – Evotec Biologics today Our vision for tomorrow Intellectual Expanding technology leadership Validated technology leadership property o
Slide 14: Fast track toward asset-lighter model
Fast track toward asset-lighter model Toulouse, France Evotec and Sandoz have signed the sale of Just – Evotec Biologics EU1, including the biologics manufacturing site (J.POD) located in Toulouse, France PAGE 14 1 Completion of transaction remains subject to consultation procedures with the French
Slide 15: Deal rationale
Deal rationale Transaction validates Evotec’s technology leadership and accelerates shift to asset-lighter model Strategic focus Transaction impact Technology • Huge endorsement by strong partner – Retaining high-value IP and core R&D competencies leadership • Leveraging technology advantage for sha
Slide 16: Attractive financial impact across multiple parameters
Attractive financial impact across multiple parameters Key deal parameters Key deal parameters, replacing existing commitments • Sale of Just – Evotec’s Biologics manufacturing site in Toulouse (J.POD)1 Scope • Technology license to operate J.POD, Toulouse based on Just – Evotec Biologics’ technolog
Slide 17: Assets in technical development
Supporting Sandoz in targeting US$ > 90 bn originator net sales JEB partnered biosimilars portfolio Originator net Loss of Exclusivity Targeted brand Indication sales (US$ bn) Darzalex® Europe: 2031 Assets in technical development Multiple Myeloma 17 daratumumab SC US: 2029 Enhertu® var. HER2-positi
Slide 18: Poised for long term growth
Poised for long term growth Next-generation CDMO model – Leveraging innovation, retaining platform control Leverage existing CDMO offerings Shaping new markets through innovation • IP licensing model for proprietary continuous manufacturing platform Full CDMO services Early and late- • Licensing of
Slide 19: Shaping the next generation CDMO model
Shaping the next generation CDMO model Accelerating growth – Enhancing margins – Improving capital return Continuation of existing commercial model ML enabled Molecule Complex Biologics Molecule Discovery Continuous mfg services Development Process Development Product Customer Traditional path enabl
Slide 20: Lever 4: Upside through returns on asset pipeline
Lever 4: Upside through returns on asset pipeline Above market growth rates at better-quality earnings Technological leadership and innovation; steering portfolio towards high value segments Commitment to Operational Excellence Accelerating cost-out plans & further productivity improvement Just – Ev
Slide 21: Asset pipeline with ~ € 16 bn opportunity (non-risk adjusted)
Asset pipeline with ~ € 16 bn opportunity (non-risk adjusted) Financial upside is becoming more tangible as pipeline broadens and assets advance Pipeline of product opportunities Existing portfolio with long-term revenue upside • >100 assets, of which 60% partnered Non-risk adjusted revenue, in € bn
Slide 22: Expecting meaningful pipeline advancements next 6-9 months
Expecting meaningful pipeline advancements next 6-9 months 13 partnered projects in pre-clinical & clinical stage, addressing markets in Onco, CNS, I&I Q1 2025 Today 2026 • Two assets in Ph III phase II in Q4 2025, expected to grow to up to four assets in Ph II Clinical 2026 • Number of assets Ph I
Slide 23: Financials
1 Pioneering Drug Discovery 2 Financials PAGE 23
Slide 24: FY 2024: Navigating a challenging year – JEB revenue +71%
FY 2024: Navigating a challenging year – JEB revenue +71% Condensed income statement FY 2024 in € m1 FY 2024 FY 2023 Change Comments External Revenues 797.0 781.4 2% Soft D&PD market; temporarily more investments in late-stage assets D&PD 611.4 673.0 (9)% Strong growth momentum of JEB based on JEB 1
Slide 25: 9M 2025: D&PD behind expectations – JEB ahead of plan
9M 2025: D&PD behind expectations – JEB ahead of plan Condensed income statement 9M 2025 in € m1 9M 2025 9M 2024 Change Comments External Revenues 535.1 575.7 (7)% Overall phasing pattern as in previous years D&PD 391.9 447.0 (12)% Soft market in early-stage drug discovery JEB 143.2 128.7 11% Broade
Slide 26: Significant reduction of net debt by end of year
Significant reduction of net debt by end of year Quarterly liquidity development Net debt, in € m 173 164 43 107 114 247 • Total liabilities and ++ lease obligations Liquidity at increased to € 484 m quarter end, 397 from € 462 m (end of in € m 371 348 Q2‘25) due to the start of a new lease in our 2
Slide 27: Guidance 2025
Guidance 20251 FY 2024 Guidance 2025 Comment Stable development driven by strong Group revenues € 797 m € 760 - 800 m JEB segment; D&PD navigating in soft market environment Further prioritisation of scalable R&D expenditure2 € 51 m € 40 - 50 m tech-platforms and technologies Improved revenue mix an
Slide 28: Promising overall development towards mid-term value creation
Promising overall development towards mid-term value creation Above market growth rates at better-quality earnings Technological leadership and innovation; steering portfolio Later tipping point towards high value segments Commitment to Operational Excellence Ahead of plan Accelerating cost-out plan
Slide 29: Mid-term Outlook
Mid-term Outlook 2028 aspiration Revenue Adj. EBITDA CAGR1 margin 2024-2028 2028 8-12% >20% (FY 2024: € 797 m) (FY 2024: ~3%) Drivers Market recovery, Operating leverage, Differentiation, Mix/Value add-ons, Value add-ons Productivity, Cost optimisation PAGE 29 1 CAGR = Compound annual growth rate
Slide 30: Appendix
Appendix PAGE 30
Slide 31: Experienced management team with long-term mission
Experienced management team with long-term mission The management team Experience Experience • 2017 – 2022 CEO of Mediq • 2018 – 2024: • 2005 – 2017 Various CFO of Mediq leadership positions at Linde • 2016 – 2017: Group, since 2007 member CFO of GE Mining of the Group Executive • 2001 – 2016: Commi
Slide 32: Global view and deep experience for best governance
Global view and deep experience for best governance Independent and diverse Supervisory Board • Since 2014 Member of • Since 2019 Member of the • Since 2022 Member of Evotec’s Evotec’s Supervisory Board Supervisory Board Supervisory Board (2021 Chairperson) (2021 Vice Chairperson) • Since 2013, Diff
Slide 33: Shareholders supporting sustainable growth
Shareholders supporting sustainable growth Shareholder structure1 ~ 10% Triton GP HoldCo SARL ~ 7% Mubadala Investment Company ~ 83% Free float Number of shares: Listings: 52 week high/low: 177.9 m Frankfurt Stock Exchange (SDAX, TecDAX), Ticker: EVT € 8.57/€ 4.90 NASDAQ Global Select Market (ADS),
Slide 34: Investor Relations contact
Dr. Sarah Fakih EVP Head of Global Communications & Investor Relations +49 (0) 151 70688784 (mobile) [email protected]